Hualan Biological Engineering Inc. (SHE:002007)
China · Delayed Price · Currency is CNY 13.17
-0.37 (-2.73%)
Aug 21, 2026, 3:04 PM CST
SHE:002007 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 24,044 | 27,649 | 30,815 | 40,471 | 41,285 | 53,162 | |
Market Cap Growth | -22.10% | -10.27% | -23.86% | -1.97% | -22.34% | -31.01% |
Enterprise Value | 22,200 | 24,568 | 28,917 | 39,272 | 40,273 | 50,356 |
Last Close Price | 13.17 | 14.57 | 15.54 | 20.06 | 20.23 | 25.79 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 28.04 | 29.40 | 28.33 | 27.32 | 38.36 | 40.93 |
Forward PE | 23.95 | 15.93 | 19.37 | 23.05 | 28.47 | 27.36 |
PS Ratio | 5.36 | 6.02 | 7.04 | 7.58 | 9.14 | 11.98 |
PB Ratio | 1.76 | 2.07 | 2.23 | 3.02 | 3.38 | 5.87 |
P/TBV Ratio | 2.11 | 2.47 | 2.67 | 3.67 | 4.09 | 6.54 |
P/FCF Ratio | 35.56 | 40.62 | 38.33 | 68.31 | 73.28 | 85.59 |
P/OCF Ratio | 28.04 | 31.49 | 29.09 | 30.07 | 43.13 | 37.11 |
PEG Ratio | 2.32 | 2.01 | 1.52 | 0.93 | 3.34 | 3.34 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.94 | 5.35 | 6.60 | 7.35 | 8.92 | 11.35 |
EV/EBITDA Ratio | 16.92 | 17.51 | 20.09 | 18.98 | 26.92 | 28.25 |
EV/EBIT Ratio | 21.47 | 21.75 | 24.53 | 21.69 | 32.92 | 31.75 |
EV/FCF Ratio | 32.83 | 36.10 | 35.97 | 66.29 | 71.49 | 81.07 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.03 | 0.07 | 0.08 | 0.09 | 0.11 |
Debt / EBITDA Ratio | 0.01 | 0.32 | 0.63 | 0.49 | 0.74 | 0.56 |
Debt / FCF Ratio | 0.01 | 0.67 | 1.13 | 1.71 | 1.97 | 1.61 |
Net Debt / Equity Ratio | -0.28 | -0.29 | -0.32 | -0.25 | -0.21 | -0.26 |
Net Debt / EBITDA Ratio | -2.87 | -2.81 | -3.12 | -1.60 | -1.74 | -1.32 |
Net Debt / FCF Ratio | -5.56 | -5.80 | -5.58 | -5.59 | -4.61 | -3.78 |
Asset Turnover | 0.28 | 0.29 | 0.27 | 0.35 | 0.34 | 0.41 |
Inventory Turnover | 0.84 | 0.93 | 0.96 | 1.11 | 1.21 | 1.21 |
Quick Ratio | 4.44 | 3.61 | 3.17 | 2.68 | 2.85 | 2.46 |
Current Ratio | 6.57 | 4.93 | 4.07 | 3.61 | 3.76 | 3.09 |
Return on Equity (ROE) | 6.61% | 7.34% | 8.48% | 13.75% | 11.73% | 16.94% |
Return on Assets (ROA) | 4.08% | 4.47% | 4.54% | 7.34% | 5.82% | 9.19% |
Return on Invested Capital (ROIC) | 9.12% | 10.24% | 10.45% | 15.57% | 13.09% | 24.42% |
Return on Capital Employed (ROCE) | 7.50% | 8.40% | 8.40% | 13.40% | 9.70% | 17.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.57% | 3.40% | 3.53% | 3.66% | 2.61% | 2.44% |
FCF Yield | 2.81% | 2.46% | 2.61% | 1.46% | 1.36% | 1.17% |
Dividend Yield | 7.49% | 6.87% | 1.29% | 1.50% | 1.48% | 0.78% |
Payout Ratio | 147.37% | 144.78% | 43.00% | 38.04% | 37.12% | 43.43% |
Buyback Yield / Dilution | 0.13% | 0.16% | -0.23% | 0.19% | 0.17% | -0.59% |
Total Shareholder Return | 7.62% | 7.03% | 1.05% | 1.69% | 1.65% | 0.19% |